Asset profile
SAR443579
Biologic (subtype unspecified)
Evidence outlook
Development stopped: Phase 1/2 study terminated
The drug's registered studies are all terminated, withdrawn or suspended (NCT06508489: terminated); none completed, so no evidence signal is assigned. Check the registry record for the sponsor's stated reason.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
66 competitors in this universe: 6 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 39 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| SAR443579: this drug | Phase 1/2 | Biologic (subtype unspecified) | CD123 | ||
| Pivekimab Sunirine | Phase 2/3 | Antibody–drug conjugate | CD123 | ||
| Tagraxofusp | Phase 2 | — | CD123 | ||
| CD123 Targeted CAR-NK Cells | Phase 1/2 | Cell therapy | CD123 | ||
| Allo-RevCAR01-T | Phase 1 | — | CD123 | ||
| Anti-CD123 CAR NK Cells | Phase 1 | — | CD123 | ||
| BYON4413 | Phase 1 | — | CD123 | ||
| ASTX727 | Approved | Small molecule | Decitabine/cedazuridine fixed combination (DNMT + CDA inhibition) | ||
| Enasidenib | Approved | Small molecule | IDH2 | ||
| Gemtuzumab Ozogamicin | Approved | Antibody–drug conjugate | CD33 | ||
| Gilteritinib | Approved | Small molecule | FLT3 | ||
| Midostaurin | Approved | Small molecule | FLT3;KIT;PKC;PDGFR | ||
| Olutasidenib | Approved | Small molecule | Mutant IDH1 | ||
| Quizartinib | Approved | Small molecule | FLT3 | ||
| Revumenib | Approved | Small molecule | Menin | ||
| Tretinoin (Vesanoid) | Approved | Small molecule | RARA (retinoic acid receptor alpha); degrades the PML-RARA fusion oncoprotein in APL |
…and 51 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.